MicroRNAs in colorectal cancer: A comparative analysis of circulating and tissue microRNA levels

Table 1 Sociodemographic, and clinical characteristics of the enrolled cohort, mean ± SD (minimum-maximum)

Features	Total (n = 19)
Age	67.58 ± 9.43 (51-83)
Sex (%, female; male)	52.6; 47.4
Localization	Ascending colon (n = 5); transverse colon (n = 2); descending colon (n = 1); sigmoid colon (n = 4); rectosigmoid junction (n = 4); rectum (n = 3)
Grading (%, G1; G2; G3)	G1 15.8; G2 52.6; G3 31.6
TNM classification	T2 N0 M0 (n = 2); T3 N0 M0 (n = 7); T3 N1 M0 (n = 7); T4A N1 M0 (n = 1); T4B N0 M0 (n = 1); T4B N1 M0 (n = 1)
Microsatellite instability (%, yes; no)	10.5; 89.5
BRAF mutation (%, yes; no)	5.3; 94.7
KRAS mutation (%, yes; no)	36.8; 63.2
Lymphovascular invasion (%, yes; no)	42.1; 57.9
Perineural invasion (%, yes; no)	26.3; 73.7
Hemoglobin (g/dL)	11.77 ± 2.84 (7.10-17.50)
White blood cells (× 103/μL)	7616.84 ± 2749.57 (4880.00-14840.00)
Platelets (× 103/μL)	287.79 ± 138.51 (152.00-777.00)
International normalized ratio	1.04 ± 0.08 (0.87-1.22)
Fibrinogen (mg/dL)	435.42 ± 129.52 (275.10-796.00)
Albumin (g/dL)	3.98 ± 0.69 (2.40-5.48)
Cholesterol (mg/dL)	161.46 ± 39.95 (73.00-227.00); available for 18 patients
Triglycerides (mg/dL)	94.19 ± 24.84 (36.00-134.00); available for 17 patients
Alanine aminotransferase (U/L)	23.86 ± 26.38 (5.62-120.00); available for 17 patients
Aspartate transaminase (U/L)	22.16 ± 11.53 (13.00-65.00); available for 18 patients
Urea (mmol/L)	36.01 ± 13.40 (15.00-59.50); available for 18 patients
Creatinine (μmol/L)	0.96 ± 0.22 (0.55-1.33); available for 18 patients
Uric acid (μmol/L)	4.91 ± 1.77 (2.30-8.91); available for 18 patients
Carcinoembryonic antigen (ng/mL)	41.18 ± 112.53 (0.65-444.00); available for 15 patients
Cancer antigen 19-9 (U/mL)	29.22 ± 50.82 (3.47-211.00); available for 16 patients
Alpha-fetoprotein (ng/mL)	3.62 ± 2.88 (1.07-9.40); available for 9 patients

TNM: Tumor-nodes-metastasis.